PNPLA2

Across TCGA pan-cancer cohorts, PNPLA2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PNPLA2 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PNPLA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PNPLA2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and UCEC are the cancer types where PNPLA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.625	0.162	.003	14	view →
HNSC	OS	Tertile	IV	0.854	0.536	.004	12	view →
UCEC	DFS	Quartile	All	0.788	1.000	.007	10	view →
LSCC	OS	Median	All	1.000	0.939	.014	6	view →
GBM	OS	Median	All	0.289	0.486	.030	4	view →
CCRCC	DFS	Median	II,III,IV	0.482	0.745	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PNPLA2–PDAC (DFS)

Open the PDAC breakdown →